Financial Performance - The company's operating revenue for Q3 2025 was approximately ¥9.88 billion, a decrease of 5.46% compared to the same period last year[6]. - The total profit for the quarter was approximately ¥1.12 billion, down 1.89% year-on-year, while the net profit attributable to shareholders increased by 4.52% to approximately ¥821.33 million[6][7]. - The net profit attributable to shareholders, excluding non-recurring gains and losses, was approximately ¥612.46 million, reflecting a year-on-year increase of 5.20%[9]. - Cash flow from operating activities for the quarter was approximately ¥1.25 billion, an increase of 15.57% compared to the same period last year[6]. - The basic and diluted earnings per share for the quarter were both ¥0.31, representing a year-on-year increase of 6.90%[6]. - For the first three quarters of 2025, the company achieved operating revenue of CNY 29.393 billion, a decrease compared to the same period last year[18]. - The net profit attributable to shareholders for the first three quarters of 2025 was CNY 2.523 billion, with a net profit of CNY 1.573 billion after deducting non-recurring gains and losses[18]. - Total operating revenue for the first three quarters of 2025 was CNY 29.39 billion, a decrease of 4.9% compared to CNY 30.91 billion in the same period of 2024[37]. - Net profit for the first three quarters of 2025 reached CNY 3.06 billion, an increase of 21.3% from CNY 2.52 billion in the first three quarters of 2024[37]. - Total comprehensive income for the period attributable to the parent company was CNY 2,242,462,807.32, an increase from CNY 1,833,394,697.38 in the same period last year, representing a growth of approximately 22.3%[38]. - Basic and diluted earnings per share increased to CNY 0.95 from CNY 0.75, reflecting a growth of 26.7% year-over-year[38]. Assets and Liabilities - The total assets of the company as of September 30, 2025, were approximately ¥118.12 billion, a slight increase of 0.56% from the end of the previous year[6]. - The equity attributable to shareholders was approximately ¥48.03 billion, up 1.62% from the end of the previous year[6]. - The company's total assets as of September 30, 2025, amounted to CNY 118.12 billion, slightly up from CNY 117.46 billion at the end of 2024[36]. - Total liabilities decreased to CNY 57.31 billion from CNY 57.53 billion year-over-year[36]. - The company’s long-term equity investments increased to CNY 26.38 billion from CNY 24.69 billion, reflecting a growth of 6.8%[36]. - The company’s total equity increased to CNY 60.81 billion from CNY 59.93 billion, indicating a growth of 1.5% year-over-year[36]. - Total liabilities increased to CNY 15,795,860,646.14 from CNY 14,947,230,943.39, representing an increase of approximately 5.7%[44]. - The total equity attributable to shareholders decreased to CNY 35,567,203,718.02 from CNY 35,728,698,458.71, a decline of about 0.45%[44]. Research and Development - Research and development expenses for the first three quarters of 2025 totaled CNY 2.730 billion, an increase of 3.08% year-on-year[19]. - The company’s total R&D investment for the first three quarters of 2025 was CNY 3.998 billion, reflecting a growth of 2.12% year-on-year[19]. - In Q3 2025, R&D expenses reached CNY 1.013 billion, marking a significant increase of 28.81% year-on-year[19]. - The company continues to focus on innovative drugs and high-end medical devices, aiming to optimize asset and financial structures through lean operations[18]. - The company’s innovative drug pipeline continues to expand, with multiple products in various stages of clinical trials and regulatory approvals[26]. - The company aims to enhance treatment options for patients with advanced cancers through its ongoing research and development efforts[21]. Shareholder Information - The controlling shareholder, Fosun High Technology, held a total of 961.424 million shares, accounting for approximately 36.00% of the total share capital at the end of the reporting period[16]. - The top ten shareholders collectively held 1.5 billion shares, with Fosun High Technology being the largest shareholder[15]. - The company completed the repurchase of 14,228,552 A shares, accounting for approximately 0.5328% of the total share capital, with a total repurchase amount of approximately RMB 348.36 million, at an average price of RMB 24.48 per share[30]. - The company repurchased 3,410,500 H shares, representing about 0.1277% of the total share capital, with a total repurchase amount of approximately HKD 47.84 million, at an average price of HKD 14.03 per share[31]. - The company approved an A-share stock option incentive plan, granting up to 5,726,100 A-share options, with the first grant not exceeding 4,580,900 options[33]. - The company approved an H-share restricted stock unit plan, granting up to 13,370,500 H-share restricted stock units, with the first grant not exceeding 10,696,400 units[34]. Regulatory Approvals and Product Development - The company received approval for a new indication of its innovative small molecule CDK4/6 inhibitor, FCN-437c, for the treatment of HR-positive, HER2-negative locally advanced or metastatic breast cancer in China[21]. - The company’s HLX14 injection was approved by the FDA and the European Commission, covering all indications previously approved for the original product, making it the first domestically produced HLX14 to gain overseas approval[22]. - The company’s innovative PD-1 inhibitor, SRL-172, achieved its primary endpoint in a Phase III clinical study for gastric cancer, supporting early market application[23]. - The company established a nuclear medicine platform, Xingrui Jingxuan, to develop integrated diagnostic and therapeutic nuclear medicine products targeting the oncology field[24]. - The company submitted a registration application for FKC889 injection for the treatment of relapsed or refractory precursor B-cell acute lymphoblastic leukemia (ALL) in adults, which was accepted by the National Medical Products Administration in September 2025[22]. - The company’s HLX43 injection received orphan drug designation from the FDA for the treatment of thymic epithelial tumors, aiding its subsequent development and commercialization in the U.S.[23]. - The company is preparing clinical trials for Ga[68Ga]PSMA-0057 and Lu[177Lu]PSMA-0057 injections as part of its nuclear medicine product pipeline[24]. - The company has initiated clinical trials for HLX79, a treatment for active renal glomerulonephritis, and HLX43, targeting advanced non-small cell lung cancer (NSCLC) in the U.S.[28].

Core Viewpoint - Fosun Pharma reported a decline in revenue for Q3 2025, primarily due to the impact of centralized drug procurement, while net profit showed a positive growth trend [1] Financial Performance - Q3 2025 revenue reached 9.879 billion yuan, a year-on-year decrease of 5.46% [1] - Net profit attributable to shareholders for Q3 2025 was 821 million yuan, an increase of 4.52% year-on-year [1] - For the first three quarters of 2025, total revenue was 29.393 billion yuan, down 4.91% year-on-year [1] - Net profit attributable to shareholders for the first three quarters was 2.523 billion yuan, reflecting a year-on-year growth of 25.50% [1] Market Impact - The decline in revenue for the first three quarters and Q3 was mainly influenced by the continuation of centralized drug procurement and the initiation of such programs in certain regions [1] - Despite the revenue decline, the income from innovative drugs showed steady growth during the same period [1]

Core Viewpoint - Fosun Pharma reported a decline in revenue for Q3 2025, while net profit showed an increase, indicating mixed financial performance [1] Financial Performance - In Q3 2025, the company achieved revenue of 9.879 billion yuan, a year-on-year decrease of 5.46% [1] - The net profit attributable to shareholders for Q3 2025 was 821 million yuan, reflecting a year-on-year increase of 4.52% [1] - Basic earnings per share for Q3 2025 stood at 0.31 yuan [1] - For the first three quarters of 2025, the total revenue reached 29.393 billion yuan, down 4.91% year-on-year [1] - The net profit attributable to shareholders for the first three quarters was 2.523 billion yuan, showing a significant year-on-year increase of 25.50% [1] - Basic earnings per share for the first three quarters was reported at 0.95 yuan [1]

复星医药公告，第三季度营收为98.79亿元，同比下降5.46%；净利润为8.21亿元，同比增长4.52%。前 三季度营收为293.93亿元，同比下降4.91%；净利润为25.23亿元，同比增长25.50%。 ...

证券之星消息，10月27日南向资金增持148.3万股复星医药（02196.HK）。近5个交易日中，获南向资金 增持的有5天，累计净增持320.05万股。近20个交易日中，获南向资金减持的有10天，累计净减持1135.8 万股。截至目前，南向资金持有复星医药（02196.HK）3.09亿股，占公司已发行普通股的56.01%。 | 交易日 | 持股总数 (股) | 持股变动(股) | 变动幅度 | | --- | --- | --- | --- | | 2025-10-27 | 3.09亿 | 148.30万 | 0.48% | | 2025-10-24 | 3.08亿 | 81.65万 | 0.27% | | 2025-10-23 | 3.07亿 | 47.35万 | 0.15% | | 2025-10-22 | 3.06亿 | 31.65万 | 0.10% | | 2025-10-21 | 3.06亿 | 11.10万 | 0.04% | 上海复星医药（集团）股份有限公司是一家主要从事医药产品研发、制造与销售的中国公司。该公司经 营五个分部。制药分部主要从事创新药、成熟医药产品制造和疫苗业务。医疗器械与医学诊 ...

证券代码：600196 股票简称：复星医药 编号：临2025-164 上海复星医药（集团）股份有限公司关于控股子公司药品获注册批准的公告 剂型：片剂 规格：90mg、360mg 注册分类：化学药品3类 上市许可持有人：上海复星医药产业发展有限公司 生产企业：苏州二叶制药有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 一、概况 近日，上海复星医药（集团）股份有限公司（以下简称"本公司"）控股子公司上海复星医药产业发展有 限公司就地拉罗司片、地拉罗司颗粒（以下简称"该等药品"）的药品注册申请获国家药品监督管理局批 准。 二、该等药品的基本情况 1、地拉罗司片 注册分类：化学药品3类 上市许可持有人：上海复星医药产业发展有限公司 生产企业：苏州二叶制药有限公司 药品批准文号：国药准字H20255758 三、该等药品的研究和上市情况 该等药品为本集团（即本公司及控股子公司/单位，下同）自主研发的化学药品，本次获批适应症为用 于治疗（1）年龄大于2岁的β-地中海贫血患者因频繁输血所致慢性铁过载、（2）10岁及10岁以上非输 血 ...

格隆汇10月24日丨复星医药(02196.HK)公告，近日，上海复星医药(集团)股份有限公司控股子公司上海 复星医药产业发展有限公司就地拉罗司片、地拉罗司颗粒(以下简称"该等药品")的药品注册申请获国家 药品监督管理局批准。 该等药品的基本情况 生产企业：苏州二叶制药有限公司 药品批准文号：国药准字H20255699、H20255700 2、地拉罗司颗粒 剂型：颗粒剂 规格：360mg 1、地拉罗司片 剂型：片剂 规格：90mg、360mg 注册分类：化学药品3类 上市许可持有人：上海复星医药产业发展有限公司 上市许可持有人：上海复星医药产业发展有限公司 生产企业：苏州二叶制药有限公司 药品批准文号：国药准字H20255758 三、该等药品的研究和上市情况 该等药品为集团(即公司及控股子公司/单位，下同)自主研发的化学药品，本次获批适应症为用于治疗 (1)年龄大于2岁的-地中海贫血患者因频繁输血所致慢性铁过载、(2)10岁及10岁以上非输血依赖性地中 海贫血综合征患者的慢性铁过载。截至2025年9月，集团现阶段针对该等药品的累计研发投入约为人民 币2,455万元(未经审计)。根据IQVIACHPA最新数据，2 ...

北京商报讯(记者王寅浩宋雨盈)10月24日，复星医药（600196）发布公告称，公司控股子公司上海复星 医药产业发展有限公司就地拉罗司片、地拉罗司颗粒的药品注册申请获国家药品监督管理局批准。本次 获批适应症为用于治疗年龄大于2岁的β-地中海贫血患者因频繁输血所致慢性铁过载以及10岁及以上非 输血依赖性地中海贫血综合征患者的慢性铁过载。 ...

注册分类：化学药品3类 上市许可持有人：上海复星医药产业发展有限公司 格隆汇10月24日丨复星医药(02196.HK)公告，近日，上海复星医药(集团)股份有限公司控股子公司上海 复星医药产业发展有限公司就地拉罗司片、地拉罗司颗粒(以下简称"该等药品")的药品注册申请获国家 药品监督管理局批准。 该等药品的基本情况 1、地拉罗司片 剂型：片剂 规格：90mg、360mg 规格：360mg 注册分类：化学药品3类 上市许可持有人：上海复星医药产业发展有限公司 生产企业：苏州二叶制药有限公司 药品批准文号：国药准字H20255758 三、该等药品的研究和上市情况 生产企业：苏州二叶制药有限公司 药品批准文号：国药准字H20255699、H20255700 2、地拉罗司颗粒 剂型：颗粒剂 该等药品为集团(即公司及控股子公司/单位，下同)自主研发的化学药品，本次获批适应症为用于治疗 (1)年龄大于2岁的β-地中海贫血患者因频繁输血所致慢性铁过载、(2)10岁及10岁以上非输血依赖性地中 海贫血综合征患者的慢性铁过载。截至2025年9月，集团现阶段针对该等药品的累计研发投入约为人民 币2,455万元(未经审计)。根据IQ ...

复星医药（600196）(02196)发布公告，近日，上海复星医药(集团)股份有限公司(以下简称"本公司")控 股子公司上海复星医药产业发展有限公司就地拉罗司片、地拉罗司颗粒(以下简称"该等药品")的药品注 册申请获国家药品监督管理局批准。 该等药品为本集团(即本公司及控股子公司/单位，下同)自主研发的化学药品，本次获批适应症为用于治 疗(1)年龄大于2岁的β-地中海贫血患者因频繁输血所致慢性铁过载、(2)10岁及10岁以上非输血依赖性地 中海贫血综合征患者的慢性铁过载。截至2025年9月，本集团现阶段针对该等药品的累计研发投入约为 人民币2,455万元(未经审计)。根据IQVIA CHPA最新数据，2024年，地拉罗司制剂于中国境内(不包括港 澳台地区)的销售额约为人民币1.28亿元。 ...